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Concerns have been raised that degradation of implants used in hip and knee arthroplasty may lead to an increased risk of some
cancers, particularly those of the haematopoietic, lymphatic and urinary systems. We used linked statistical records of hospital
admissions and deaths to compare cancer rates in cohorts of people who had undergone hip or knee arthroplasty with a comparison
cohort. We did not find an elevated risk for cancer, overall, in either the hip or knee cohort or in both combined (rate ratio for both
combined 0.99; 95% confidence intervals 0.95–1.02), or for haematopoietic, lymphatic or urinary system cancers. There was also no
elevation in risk of cancer more than 10 years after arthroplasty. Our findings add to the evidence that arthroplasty is safe in respect
of cancer risk.
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Hip and knee arthroplasties are now very common operations. It
would be important, both from clinical and public health
perspectives, if they increased the risk of cancer. There has
been long-standing interest in whether prolonged contact between
body tissue and plastic and metal prostheses does increase the
risk of cancer. Corrosion and normal wear and tear of prostheses
are known to liberate polyethylene and metallic particles (Sunder-
man, 1989; Jacobs et al, 1998; Urban et al, 2000). If these have
any pathological effect, it is thought that the corrosion products
are most likely to affect the haematopoietic, lymphatic and urinary
systems. An early cohort study showed a significant long-term
elevation of haematopoietic and lymphatic cancers after hip
arthroplasty (Gillespie et al, 1988). It also showed a deficit
of breast and colorectal cancer (Gillespie et al, 1988). Several
studies of hip and knee arthroplasty have been published since
then, summarised by Visuri et al (2003), and a meta-analysis has
been published combining the data from six Nordic studies (Visuri
et al, 2003). The meta-analysis reported a small but significant
deficit of cancers, overall, with significant deficits of lung,
laryngeal, stomach and colorectal cancers. The presumed explana-
tion was that the deficits reflected aspects of ‘healthy lifestyle’ of
people who eventually need joint replacement. The authors of the
meta-analysis also reported that the combined data showed a small
but significant elevation of endometrial cancer, prostate cancer
and skin melanoma in people who had undergone joint replace-
ment.
To add to the evidence on cancer following joint replacement,
we used the Oxford record linkage study (ORLS) to determine
rates of cancers in people after hip or knee arthroplasty.
METHODS
Population and data
The Oxford Record Linkage Study (ORLS) includes brief statistical
abstracts of records of all hospital admissions (including day
cases) in National Health Service (NHS) hospitals, and all deaths
regardless of where they occurred, in defined populations within
the former Oxford National Health Service Region from January
1963 to March 1999 (Goldacre et al, 2000). The hospital data were
collected routinely in the NHS as the Oxford Regional Health
Authority’s hospital discharge statistics. The death data were
derived from death certificates. Data collection covered part of one
health district and its associated hospitals from 1963 (population
350000), two districts from 1966 (population 850000), six districts
from 1975 (population 1.9 million) and all of the region’s districts
from 1987 (population 2.5 million). With the agreement of the
Region’s Data Protection Steering Group, the data for each
individual were linked together routinely, as records accrued, as
part of the region’s health information system. The data are now
anonymised and archived.
The hip and knee arthroplasty cohorts were obtained by
identifying statistical records of individuals who had been
admitted to NHS hospitals for these operations. A reference
cohort was constructed by selecting records of admission for
various other medical and surgical conditions (see footnote of
Table 2). This is based on our ‘reference’ group of conditions that
has been used in other studies of inter-relationships between
diseases (Goldacre et al, 2000). We searched the database for any
subsequent NHS hospital care for, or death from, cancers in these
cohorts. We excluded from the analysis anyone in the arthroplasty
and reference cohorts who had a previous record of cancer or who
had cancer on the record of admission for the arthroplasty or
reference condition. We considered that rates of cancer in the
reference cohort would approximate those in the general popula-
tion of the region, while allowing for migration in and out of it
(data on migration of individuals were not available). Following
the practice of others (Visuri et al, 2003), we excluded the first year
Received 11 October 2004; revised 10 February 2005; accepted 13
February 2005
*Correspondence: Professor MJ Goldacre;
E-mail: michael.goldacre@dphpc.ox.ac.uk
British Journal of Cancer (2005) 92, 1298–1301
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
yof results to reduce the possibility that any of the patients who
underwent the operations might have had undiagnosed cancer at
the time of the surgery.
Statistical methods
We calculated rates of cancer based on person-years at risk. We
took ‘date of entry’ into each cohort as the date of first admission
for hip or knee arthroplasty or reference condition, and ‘date of
exit’ for the analysis of cancer as the date of the first record of
cancer (if any occurred), death, or 31 March 1999, whichever was
the earliest. We calculated rates for each cancer in each
arthroplasty cohort and in the reference cohort, standardising
the rates by age (in 5-year age groups), sex, calendar year of first
recorded admission and district of residence, using the combined
hip or knee arthroplasty and reference cohorts as the standard
population. We then calculated the ratio of the standardised rate of
occurrence of cancer in the hip or knee arthroplasty cohort relative
to that in the reference cohort. The confidence interval for the rate
ratio and w
2 statistics for its significance were calculated as
described elsewhere (Breslow and Day, 1987). We took Po0.05 as
the initial level of statistical significance but, for those compar-
isons without a prior hypothesis, we also adjusted the probability
values using the Bonferroni correction to allow for multiple
comparisons.
We studied the results for each condition in the reference cohort
separately, as well as in combination, to ensure that no individual
condition disproportionately influenced the ‘expected’ number of
people with subsequent cancer.
RESULTS
There were 33691 patients in the hip arthroplasty cohort, 10182
in the knee arthroplasty cohort and 475555 in the
reference (control) cohort. Table 1 summarises the age distribution
of patients in both cohorts. Patients who entered the hip
replacement cohort had an average age of 69 years and those
who entered the knee replacement cohort had an average age of 67
years. The average periods of follow up were, respectively, 7.7 and
5.4 years.
Hip arthroplasty
There was no elevation of the overall risk of cancer in people who
had undergone hip arthroplasty (Table 2): the rate ratio for all
cancers combined was 0.98 (95% confidence intervals 0.94–1.01).
A statistically significant deficit of lung cancer was found: rate
ratio 0.86 (95% confidence interval 0.78–0.95).
Considering the cancers for which there was a prior hypothesis
about elevation of risk related to arthroplasty particles, we found
that the rate ratios were not significantly different from one. The
rate ratio for lymphoma was 1.01 (0.82–1.24), for leukaemia 0.94
(0.75–1.15), for bladder cancer 0.99 (0.86–1.15) and for renal
cancer 0.93 (0.69–1.24). Considering other cancers where the
published literature has suggested that there may be a different
risk from that in the general population, there were no significant
differences in our study for cancers of the body of uterus, prostate,
malignant melanoma or other skin cancer (Table 2).
For cancers that were first recorded at least 10 years after
hip arthroplasty, the overall rate ratio was significantly less
than one (0.86: 752 observed cancers, 871 expected; 95%
confidence intervals 0.80–0.92). The rate ratio for lung cancer
was 0.64 (82 observed, 128 expected; 0.51–0.80) and there was no
elevation of risk for lymphoma (0.87; 0.56–1.30), leukaemia (0.99;
0.67–1.41), bladder cancer (0.94; 0.70–1.22) or renal cancer (0.71;
0.34–1.30).
Knee arthroplasty
There was no elevation of the overall risk of cancer in people
who had undergone knee arthroplasty (Table 3): the rate ratio
was 1.05 (0.97–1.14). That for cancer in people at least
10 years after knee arthroplasty was 1.07 (0.86–1.33). Of the 33
cancers studied, nonmelanoma skin cancer (rate ratio
1.35; P¼0.011) and pancreatic cancer (rate ratio 1.76;
P¼0.0002) were found to be significantly high. The latter
remained significant when the Bonferroni correction was used to
adjust for multiple comparisons (P¼0.007). There was a
nonsignificant elevation of risk for lymphoma 10 or more years
after knee arthroplasty (five observed, 2.6 expected; rate ratio 1.92:
0.62–4.49). There was no elevation of risk for leukaemia (0.80;
0.10–2.89).
DISCUSSION
The strengths of our study are that it is large and population-
based. Although confined to hospitalised patients, arthroplasty and
the vast majority of the cancer outcomes are conditions for which
people are admitted to hospital. A potential weakness is that we do
not have data about either hospital care for or death of people who
migrate out of the region. We have to assume that the arthroplasty
cohorts and the reference cohort are acceptably comparable in
respect of migration.
Our study has a number of other limitations. We do
not have data about socioeconomic status or about lifestyle factors
such as exercise, smoking and alcohol consumption. However,
as we discuss below, the findings that we would seek to explain in
terms of such confounding, if we could, are those that
show numerically small deficits or excesses of cancers that tend
to be lifestyle-related and not those that have been hypothesised to
be caused by arthroplasty. The finding in our cohort that
lung cancer occurred less often than expected after hip replace-
ment was also noted in the meta-analysis by Visuri et al (2003)
and in another Swedish record-linkage study (Paavolainen et al,
1999). It is likely that patients who undergo joint replacements
have, typically, led more active than average lifestyles. They
are therefore less likely than average to have been smokers.
It has also been suggested that physical activity, independently
of smoking, may decrease the risk of lung cancer in men (Lee
et al, 1999). Furthermore, patients selected for an elective
operation are assessed and deemed to be healthy enough
to warrant operation: there may be a selection effect for healthy
Table 1 Number of people admitted to hospital for hip or knee
arthroplasty in each age group
Hip arthroplasty Knee arthroplasty
Age groups (years) No. % No. %
o40 676 2 176 1.7
40–49 1144 3.4 257 2.5
50–54 1468 4.4 341 3.3
55–59 2541 7.5 732 7.2
60–64 4152 12.3 1243 12.2
65–69 5280 15.7 1873 18.4
70–74 6041 17.9 2249 22.1
75–79 5642 16.7 1928 19
80–84 3979 11.8 1049 10.3
85+ 2768 8.2 334 3.3
Total 33691 100 10182 100
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skin cancer was more common in the knee arthroplasty
cohort than in the reference cohort. There is some
consistency across studies in the finding of a positive associa-
tion between arthroplasty and skin cancer (Nyre ´n et al,
1995; Signorello et al, 2001; Visuri et al, 2003). The most plausible
explanation is that people who eventually need arthroplasty
have typically been more active than average and have also
typically spent more than average periods of time exposed to
sunlight.
Associations found between joint replacement and
cancer in some other studies – cancers of the uterus,
prostate and kidney – were not found in our study. Our
finding that cancer of the pancreas was associated with knee
replacement has not been noted in other studies. We recognise
that we made a wide range of comparisons, but, as the result
for cancer of the pancreas was highly significant
(Bonferroni corrected P-value 0.0066), this result may not be
due to chance alone. This association needs to be confirmed or
reputed elsewhere.
Suspicions about a possible causal association between
joint replacements and cancer are largely concerned with
the effects of metal implants (Sunderman, 1989; Jacobs
et al, 1998; Urban et al, 2000). It has been suspected that
minute, free-roaming particles, resulting from wear and tear,
could have carcinogenic effects and, in particular, might
increase the risk of lymphoma, leukaemia and cancer
of the urinary tract. Our findings add to the accumulating evidence
that arthroplasty is in fact safe in these respects, at least
within a period of several years. However, longer follow-up than
that currently available from the published studies would be
prudent.
Table 2 Occurrence of cancer in people who had undergone hip replacement at least a year before: number of people in the reference cohort
a with each
cancer, observed and expected number of people with cancer in the hip replacement cohort, ratio of rates in the hip replacement cohort to that in the
reference cohort, and 95% confidence intervals for the rate ratio
Cancer (ICD code)
b
Number in
cohort
Person-years of
follow-up
c
Observed
number in hip
replacement
Expected
number in hip
replacement
Adjusted rate
ratio
d
95% confidence
interval
All cancers (140–208) 25047 5616936 3015 3077 0.98 0.94–1.01
Upper gastrointestinal (140–141, 143–146,
148–149)
342 5727181 49 49.4 0.99 0.72–1.34
Salivary gland (142) 99 5728311 5 8.5 0.59 0.19–1.37
Nasopharynx (147) 47 5729341 3 4.1 0.73 0.15–2.14
Oesophagus (150) 875 5728584 128 111 1.15 0.96–1.37
Stomach (151) 1507 5727192 179 192 0.93 0.80–1.08
Colon (153) 1797 4580723 400 402 0.99 0.89–1.11
Rectum (154) 1040 4583626 207 226 0.89 0.76–1.04
Liver (155) 320 5729463 50 41.9 1.19 0.89–1.57
Pancreas (157) 903 5728968 138 130 1.06 0.89–1.25
Lung (162) 4360 5725374 417 487 0.86 0.78–0.95
Breast (174, 175) 2432 5711342 380 390 0.97 0.88–1.08
Cervix (180) 221 2311285 25 28.2 0.89 0.57–1.31
Uterus (182) 385 2310745 76 68.2 1.11 0.88–1.39
Ovary (183.0) 139 2314062 25 21.3 1.17 0.76–1.73
Prostate (185) 2435 3407301 264 247 1.07 0.93–1.19
Testis (186) 142 3413649 0 2.4 0.00 0–1.54
Kidney (189.0, 189.1) 515 5727480 47 50.3 0.93 0.69–1.24
Bladder (188) 1770 5718361 194 195 0.99 0.86–1.15
Malignant melanoma (172) 399 5726836 39 39.8 0.98 0.70–1.34
Other skin cancer (173) 1967 5712787 237 245 0.97 0.86–1.15
Brain (malignant) (191) 456 5728457 40 37.9 1.06 0.75–1.44
Other nervous system (192) 56 5729228 6 3.7 1.62 0.60–3.53
Thyroid (193) 111 5728176 13 8.3 1.57 0.83–2.68
Bone (170) 160 5728776 14 16.8 0.83 0.46–1.40
Lymphoma (200–202) 937 5724562 97 95.8 1.01 0.82–1.24
Non-Hodgkin’s lymphoma (200, 202) 828 5726174 95 91.8 1.03 0.84–1.27
Hodgkin’s disease (201) 164 5727694 13 8 1.63 0.87–2.78
Multiple myeloma (203) 473 5728484 79 65.1 1.21 0.96–1.51
Leukaemia (204–208) 834 5727030 91 97.2 0.94 0.75–1.15
Lymphoid leukaemia (204) 398 5727893 37 42.2 0.88 0.62–1.21
Myeloid leukaemia (205) 427 5728884 49 50.9 0.96 0.71–1.27
Brain (benign) (225) 255 5725456 16 19.4 0.82 0.47–1.34
aConditions used in reference cohort, with Office of Population, Censuses and Surveys (OPCS) code edition 3 for operations and ICD9 code for diagnosis (with equivalent
codes used for other coding editions): tonsillectomy/adenoidectomy (OPCS 230–236), cataract (ICD9 366), squint (ICD9 378), otitis externa, otitis media (ICD9 380–382),
haemorrhoids (ICD9 455; excluded from reference cohort for analyses of colorectal cancers), varicose veins (ICD9 454), upper respiratory tract infections (ICD9 460–466),
deflected septum, nasal polyp (ICD9 470–471), impacted tooth and other disorders of teeth (ICD9 520–521), inguinal hernia (ICD9 550; excluded from reference cohort
for analyses of colorectal cancers), ingrowing toenail and other diseases of nail (ICD9 703), sebaceous cyst (ICD9 706.2), internal derangement of knee (ICD9 717),
bunion (ICD9 727.1), selected fractures (ICD9 810–816, 823–826), dislocations, sprains and strains (ICD9 830–839, 840–848), superficial injury and contusion (ICD9 910–
919, 920–924).
bICD 9 codes for each cancer (equivalent codes were used for cases coded in ICD Revisions 7, 8 and 10.).
cPerson-years of follow-up vary a little between
cancers because of different dates of onset and therefore of ‘exit’ from the analysis.
dAdjusted for sex, age in 5-year bands, district of residence and time period in single calendar
years.
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